Downloads: 119

Files in This Item:
File Description SizeFormat 
srep45124.pdf392.63 kBAdobe PDFView/Open
Title: Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients
Authors: Nomizo, Takashi
Ozasa, Hiroaki  kyouindb  KAKEN_id
Tsuji, Takahiro
Funazo, Tomoko
Yasuda, Yuto
Yoshida, Hironori
Yagi, Yoshitaka
Sakamori, Yuichi
Nagai, Hiroki
Hirai, Toyohiro  kyouindb  KAKEN_id
Kim, Young Hak  kyouindb  KAKEN_id
Author's alias: 小笹, 裕晃
阪森, 優一
永井, 宏樹
平井, 豊博
金, 永学
Keywords: Immunosuppression
Non-small-cell lung cancer
Issue Date: 23-Mar-2017
Publisher: Springer Nature
Journal title: Scientific Reports
Volume: 7
Thesis number: 45124
Abstract: This study was intended to determine the efficacy of nivolumab, we evaluated treatment response with respect to PD-1/PD-L1 SNPs among patients with NSCLC. A total of 50 patients with NSCLC were treated with nivolumab and were also evaluated for PD-1/PD-L1 single nucleotide polymorphisms (SNPs) from plasma DNA. We investigated the association among PD-1/PD-L1 SNPs, objective response rate (ORR) and progression-free survival (PFS). Two of seven SNPs studied showed association with ORR and PFS, with maximum evidence at the marker rs2282055. The ORR was 25%, 15%, and 0% for the G/G, G/T and T/T genotypes of PD-L1 rs2282055, respectively. The G allele of PD-L1 rs2282055 was significantly associated with better clinical response compared with the T allele (P = 0.0339 [Cochran-Armitage trend test]). The median PFS time was 2.6 months (95% confidence interval [CI], 1.8 months to 4.3 months) for the G/G and G/T genotypes and 1.8 months (95% confidence interval [CI], 0.4 months to 2.2 months) for the T/T genotype (P = 0.0163). Moreover, the C/C and C/G genotypes of PD-L1 rs4143815 were significantly associated with better ORR and PFS in NSCLC patients treated with nivolumab. These results suggest that rs2282055 and rs4143815 may be a biomarker for the efficacy of nivolumab.
Rights: © The Author(s) 2017. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit
DOI(Published Version): 10.1038/srep45124
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.